Clinical Trials Targeting Specific Cancers
Lurbinectedin, approved as Zepzelca for small cell lung cancer (SCLC), shows promise in combinations with immunotherapy like pembrolizumab (Keytruda) or atezolizumab (Tecentriq) primarily for SCLC and extensive-stage SCLC (ES-SCLC). Ongoing phase 2 and 3 trials test this combo as first-line maintenance or second-line therapy after platinum failure, aiming to extend progression-free survival in relapsed/refractory cases.[1][2]
Evidence in Small Cell Lung Cancer
Most data focuses on SCLC, where lurbinectedin inhibits DNA repair in tumor cells, synergizing with PD-1/PD-L1 inhibitors to boost immune response. The IMforte trial (NCT04798250) evaluates lurbinectedin plus pembrolizumab in ES-SCLC post-induction chemo, while LAGOON (NCT04912738) compares lurbinectedin/atezolizumab maintenance against atezolizumab alone. Early results suggest improved response rates in platinum-sensitive SCLC.[2][3]
Expansion to Other Thoracic Cancers
Trials explore non-small cell lung cancer (NSCLC), especially with high PD-L1 expression. A phase 1/2 study (NCT03394021) combines lurbinectedin with pembrolizumab in advanced NSCLC, reporting partial responses in PD-L1-positive patients. Thymic carcinoma and mesothelioma also appear in basket trials, leveraging lurbinectedin's activity in transcriptionally addicted tumors.[1][4]
Potential in Solid Tumors Beyond Lung
Preclinical and early-phase data indicate benefit in ovarian cancer, particularly high-grade serous types, where lurbinectedin restores platinum sensitivity before immunotherapy. Phase 2 trials (e.g., NCT02817662) test it with pembrolizumab in platinum-resistant ovarian cancer. Triple-negative breast cancer (TNBC) and endometrial cancer show exploratory activity in immunotherapy combos due to homologous recombination deficiencies.[3][5]
Cancers with Limited or Negative Data
No strong evidence supports use in hematologic cancers or colorectal cancer; trials exclude microsatellite stable tumors due to low immunotherapy response. Prostate and pancreatic cancers lack dedicated studies, as lurbinectedin targets SINE transcription factors more active in neuroendocrine-like solid tumors.[1]
Ongoing Trials and Regulatory Outlook
Over 20 active trials on ClinicalTrials.gov pair lurbinectedin with immunotherapies across SCLC (60%), NSCLC (20%), and others like ovarian/SCLC variants. FDA fast-track status for SCLC combos could lead to approvals by 2025-2026, but broader labels depend on phase 3 readouts.[2][6]
[1]: ClinicalTrials.gov - Lurbinectedin trials
[2]: ASCO Abstracts - IMforte/LAGOON updates
[3]: PubMed - Lurbinectedin + IO reviews
[4]: NCT03394021 trial page
[5]: NCT02817662 trial page
[6]: FDA Oncology Approvals